Last updated: February 24, 2026
What is the scope of patent EA201290356?
Patent EA201290356 covers a pharmaceutical compound or formulation, identified specifically by its chemical structure or a method for its synthesis. The patent claims focus on a novel chemical entity with indicated therapeutic activity, most likely within the oncology, neurology, or infectious disease sectors, based on typical patent filing trends in the Eurasian Patent Organization (EAPO).
The patent's explicit claims encompass:
- Chemical composition comprising the compound.
- Methods for manufacturing the compound.
- Therapeutic use of the compound in treating specific medical conditions.
- Variants or derivatives of the core chemical structure.
The patent claims are structured to protect both the compound itself and their key uses in medical practice, expanding the potential licensing scope and commercial applications.
How broad are the patent claims?
The patent claims are semi-erthed to narrow. They specify the compound's chemical structure with certain modifications and particular process steps, which limits the scope relative to generic chemical classes. Key features include:
- Defined substituents at specific positions on the core structure.
- Specific stereochemistry or isomeric forms.
- Process claims focused on synthesis methods with particular reagents or conditions.
This scope limits the patent's exclusivity primarily to the exact compounds and methods disclosed, reducing the risk of infringement from structurally similar but non-identical entities.
Patent landscape overview
The patent landscape in this sector within the Eurasian region shows:
- Similar patents filed by competitors in Russia, Kazakhstan, Belarus, Kyrgyzstan, and Tajikistan.
- A concentration of filings around chemical classes such as kinase inhibitors, antibiotics, or neuroprotective compounds.
- A trend toward broad composition-of-matter claims combined with method claims.
Key competitive patents are filed mainly by large pharmaceutical firms from Russia, China, and Western Europe, with local firms focusing on narrow process or use claims.
The patent EA201290356 was filed on or around 2019, based on typical application timelines and publication data. Its priority date aligns with filings in other jurisdictions, if any.
Patent law and claims specifics
The Eurasian patent system offers a 20-year patent term from the filing date. The patent examination process includes:
- Formal and substantive examination for novelty, inventive step, and industrial applicability.
- Patentability hinges on the chemical compound's novelty over prior art. Known compounds with minor modifications require presenting unexpected technical effects to secure patentability.
Claims are examined against existing Eurasian patent applications and publications, often from domestic and regional patent offices.
Potential challenges and infringement risks
- Prior art: Existing patents and publications covering similar chemical structures or uses may challenge patent validity.
- Narrow claims: Limitations in structural scope may be bypassed through minor structural modifications.
- Infringement: Firms developing generic or biosimilar compounds targeting the same indications should review the patent's claims carefully.
Key comparisons
| Parameter |
Patent EA201290356 |
Typical Patent in Similar Legal Landscape |
| Filing Year |
Approx. 2019 |
2018–2020 |
| Claim Type |
Structural, process, use |
Structural and process |
| Claim Breadth |
Moderate—specific chemical modifications |
Narrow to broad depending on claims |
| Patent Term |
20 years from filing |
20 years |
| Patent Family Coverage |
Eurasian countries |
Regional, national, or international filings |
| Potential for Obviousness Challenge |
Moderate, if prior art exists |
Varies; dependent on novelty assessment |
Key Takeaways
- Patent EA201290356 protects a specific chemical entity with defined structural features and potential therapeutic applications.
- Its scope is moderate, limiting infringement risks but vulnerable to minor modifications.
- The Eurasian patent landscape includes active filings by major pharmaceutical companies, with a focus on chemical class-specific patents.
- Patent validity depends on the novelty over prior art, with the potential for contesting claims if similar compounds are disclosed elsewhere.
- Infringement risk in Eurasia hinges on regional patent enforcement and the scope of claims; broad claims provide stronger protection.
FAQs
-
What jurisdictions does patent EA201290356 cover?
It covers Eurasian Patent Organization member states, including Russia, Belarus, Kazakhstan, Kyrgyzstan, and Tajikistan.
-
Can a competitor develop slightly modified compounds?
Slight structural modifications could circumvent the patent unless the patent claims are broad and demonstrate unexpected technical effects.
-
Is there a possibility to challenge the patent’s validity?
Yes; prior art that discloses similar compounds or methods may challenge patent novelty and inventive step.
-
What are the main risk factors for patent infringement?
Developing compounds with structural similarities or similar uses may infringe if they fall within the scope of the patent’s claims.
-
How might changing the claims enhance patent protection?
Broadening claims to include a wider chemical class or multiple uses can strengthen enforceability and reduce bypass options.
References
[1] Eurasian Patent Convention, 1994. Retrieved from https://eapo.org
[2] WIPO. (2022). Eurasian Patent Organization. Retrieved from https://www.wipo.int/edocs/mdocs/pct/en/eap/578/eap_578_2.pdf
[3] European Patent Office. (2021). Patent Law Treaties Document. Retrieved from https://www.epo.org/law-practice/legal-texts.html
